Publications by authors named "Kamel Hacene"

Claim this Profile
C
Comparison of fifteen immunoassays for the measurement of serum MUC-1/CA 15-3 in breast cancer patients.
Marie-France Pichon, Gaëlle Le Brun, Kamel Hacene, Jean-Pierre Basuyau, Jean-Marc Riedinger

Clin Chem Lab Med· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
Frédéric Triebel, Kamel Hacene, Marie-France Pichon

Cancer Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.
Marie-France Pichon, Kamel Hacene, Sylvie Guepratte, Rainer Neumann

Clin Lab· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
Anne Bethune-Volters, Marc Labroquere, Sylvie Guepratte, Kamel Hacene, Rainer Neumann

Anticancer Res· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Frédérique Spyratos, Cécile Bouchet, Magali Ferrero-Poüs, Michèle Tubiana-Hulin, Kamel Hacène

J Natl Cancer Inst· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two prognostic groups of inflammatory breast cancer have distinct genotypes.
Florence Lerebours, Philippe Bertheau, Ivan Bieche, Louis-François Plassa, Marie-Helene Champeme, Kamel Hacene

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas.
Geri Meduri, Nathalie Charnaux, Frederique Spyratos, Kamel Hacene, Hugue Loosfelt

Cancer· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of chromosome regions and gene involvement in inflammatory breast cancer.
Florence Lerebours, Philippe Bertheau, Ivan Bieche, Keltouma Driouch, Hugues De The, Kamel Hacene

Int J Cancer· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Frédérique Spyratos, Magali Ferrero-Poüs, Martine Trassard, Kamel Hacène, Edelmira Phillips

Cancer· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis